

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.
Form 6-K
September 24, 2004

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of September 2004

AETERNA ZENTARIS INC.

(Formerly named AETerna Laboratories Inc.)

1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F X
----- -----

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes No X
----- -----

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82-_____

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

1. Press release dated September 23, 2004 - Aeterna Zentaris to Present at Upcoming Scientific and Investment Conferences
-

[LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 577-7697
www.aeternazentaris.com

PRESS RELEASE
For immediate release

AETERNA ZENTARIS TO PRESENT AT UPCOMING SCIENTIFIC AND INVESTMENT CONFERENCES

Data on Perifosine at the Strategic Research Institute's 2nd Annual
Angiogenesis Conference
Corporate Update at UBS Global Life Sciences Conference

QUEBEC CITY, CANADA, SEPTEMBER 23, 2004 - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) announced today that Dr. Jurgen Engel, Executive Vice-President, Global Research & Development and Chief Operating Officer of the Company, will make a presentation on perifosine, an oral, first-in-class AKT inhibitor currently in Phase II trials for multiple types of cancer, on Monday, September 27 at 2:45 p.m. ET, during the Strategic Research Institute's 2nd Annual Angiogenesis Conference at the Hyatt Regency Cambridge Hotel in Cambridge, Massachusetts.

Furthermore, on Thursday, September 30, Gilles Gagnon, Aeterna Zentaris' President and Chief Executive Officer will present a corporate update at the UBS Global Life Sciences Conference at 2:00 p.m. ET, which will be held at the Grand Hyatt Hotel in New York City. A live webcast of the presentation will be available on the Company's website at www.aeternazentaris.com in the Investors section. A replay of the webcast will be available through October 30, 2004 at the same address.

ABOUT AETERNA ZENTARIS INC.

Aeterna Zentaris Inc. is a biopharmaceutical company focused in oncology and endocrine therapy. Its extensive portfolio, from drug discovery to marketed products, includes perifosine, an orally-active AKT inhibitor in several Phase II trials for multiple cancers, and cetorelix, an LHRH antagonist already marketed for IN VITRO fertilization under the brand name Cetrotide(R), and also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH).

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

AEterna Zentaris also owns 62% of Atrium Biotechnologies Inc., which develops, distributes and markets active ingredients, specialty fine chemicals, cosmetic and nutritional products for the cosmetics, chemical, pharmaceutical and nutritional industries.

[LOGO]

News releases and additional information about AEterna Zentaris are available on its new Web site www.aeternazentaris.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

Contacts:

MEDIA RELATIONS

Paul Burroughs
(418) 652-8525 ext. 406
paul.burroughs@aeternazentaris.com

INVESTOR RELATIONS

Jacques Raymond
(418) 652-8525 ext. 360
jacques.raymond@aeternazentaris.com

U.S. INVESTOR RELATIONS

Lippert/Heilshorn & Associates
Kim Golodetz
(212) 838-3777
kgolodetz@lhai.com

EUROPE

Matthias Seeber
+49 69 42602 3425
matthias.seeber@zentaris.de

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

DATE: SEPTEMBER 23, 2004

By: /S/MARIO PARADIS

Mario Paradis
Senior Finance Director and Corporate Secretary